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Objective: To compare survival in post-myocardial (MI) participants from the Enhancing Recovery In Coronary Heart Disease
(ENRICHD) clinical trial with a first episode of major depression (MD) and those with recurrent MD, which is a risk factor for
mortality after acute MI. Recent reports suggest that the level of risk may depend on whether the comorbid MD is a first or a
recurrent episode. Methods: Survival was compared over a median of 29 months in 370 patients with an initial episode of MD,
550 with recurrent MD, and 408 who were free of depression. Results: After adjusting for an all-cause mortality risk score, initial
Beck Depression Inventory score, and the use of selective serotonin reuptake inhibitor antidepressants, patients with a first episode
of MD had poorer survival (18.4% all-cause mortality) than those with recurrent MD (11.8%) (hazard ratio (HR)  1.4; 95%
Confidence Interval (CI)  1.0–2.0; p  .05). Both first depression (HR  3.1; 95% CI  1.6–6.1; p  .001) and recurrent MD
(HR  2.2; 95% CI  1.1–4.4; p  .03) had significantly poorer survival than did the nondepressed patients (3.4%). A secondary
analysis of deaths classified as probably due to a cardiovascular cause resulted in similar HRs, but the difference between
depression groups was not significant. Conclusions: Both initial and recurrent episodes of MD predict shorter survival after acute
MI, but initial MD episodes are more strongly predictive than recurrent episodes. Exploratory analyses suggest that this cannot be
explained by more severe heart disease at index, poorer response to depression treatment, or a higher risk of cerebrovascular disease
in patients with initial MD episodes. Key words: depression, depression history, acute myocardial infarction, mortality.
MI  myocardial infarction; MD  major depression; ENRICHD 
Enhancing Recovery In Coronary Heart Disease; DISH  Depres-
sion Interview and Structured Hamilton; BDI  Beck Depression
Inventory; HR  hazard ratio; SSRI  selective serotonin reuptake
inhibitor; HAM-D  Hamilton Rating Scale for Depression; UC 
usual care; LVEF  left ventricular ejection fraction; ACS  acute
coronary syndrome; HADS  Hospital Anxiety and Depression Scale.
INTRODUCTION
N
umerous studies have established depression as a risk
factor for mortality post acute myocardial infarction (MI)
(1–3), although a few studies have failed to replicate these
findings (3). One possible explanation for the negative
findings is that not all patients with depression are at high
risk for mortality, and the proportion of truly high-risk
depressed patients may vary across samples. One of the
factors that may affect the level of risk is whether the major
depressive episode at the time of the MI is the patient’s
first; that is, whether a patient has a history of major
depressive episodes before their index MI, or whether the
episode occurring in conjunction with the MI is the first
episode (4,5).
In the first study to address this question, Lespe ´rance and
colleagues found that patients with recurrent major depression
(MD) tended to be at higher risk for mortality than those with
an initial episode (6). This finding was not unexpected: the
more exposure to a risk factor, the higher the risk. Having
hypertension for 10 years, for example, is associated with a
higher risk than having it for 1 year. Thus, depressed patients
with a history of earlier depressive episodes, and therefore
more exposure to its cardiotoxic effects, should be at greater
risk for cardiac events than those with a first episode. How-
ever, three recent studies have found that initial episodes of
depression may carry more risk than recurrent depression (7–9).
Recent clinical trials have provided evidence that patients
with a recurrent depressive episode post MI may respond
better to antidepressants than those with an initial episode
(10,11). It is possible, therefore, that patients with a first
episode of depression have a form of depression that is less
responsive to standard treatments. These patients may be at
higher risk for mortality post MI because their depressions are
more likely to persist even if treated.
The primary purpose of this study was to examine the
relationship between initial versus recurrent MD and survival
in post-MI patients who were enrolled in the Enhancing Re-
covery In Coronary Heart Disease (ENRICHD) clinical trial.
The secondary aims were to explore medical, demographic,
and psychiatric differences between these subgroups to gen-
erate hypotheses about why medical prognosis may differ
because of depression history and to determine whether de-
pression history affects response to treatment.
METHODS
Subjects
Patients admitted between October 1996 and October 1999 to coronary
care units at eight ENRICHD clinical trial sites (Washington University, St.
Louis, Missouri; Duke University, Durham, North Carolina; Harvard Univer-
sity, Boston, Massachusetts/Yale University, New Haven, Connecticut [com-
bined]; Stanford University, Stanford, California; University of Miami, Miami,
Florida; University of Alabama, Birmingham, Alabama; University of Washing-
ton, Seattle, Washington; and Rush Presbyterian Hospital, Chicago, Illinois) for
an acute MI were screened for eligibility within 28 days after hospital admission.
The study protocol was approved by the Institutional Review Boards from each
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Copyright © 2009 by the American Psychosomatic Societyparticipating site. MI was documented by cardiac enzymes and by chest pain
compatible with acute MI, characteristic evolutionary ST-T changes, or new Q
waves. Details of the methods and design of the ENRICHD clinical trial are
available elsewhere (12,13). Patients were excluded from the ENRICHD
trial if they:
a) had other life-threatening medical illnesses, cognitive impairment,
other major psychiatric disorders, or were at imminent risk of suicide;
b) were too ill or unable to participate due to logistical barriers;
c) had been taking an antidepressant for 14 days; or
d) were exempted by their cardiologist from participating in the study.
Procedures
Patients who fulfilled the eligibility criteria and provided their informed
consent were administered the ENRICHD social support instrument (12) and
the Depression Interview and Structured Hamilton (DISH) (14). The DISH is
a semistructured interview that was developed for ENRICHD to diagnose
current depressive episodes in cardiac patients according to the Diagnostic
and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV) criteria, to
determine the severity of depression using the 17-item Hamilton Rating Scale
for Depression (HAM-D), and to screen for other psychiatric disorders. The
interview also is designed to differentiate between first and recurrent major
depressive episodes. There is a high level of diagnostic agreement between
DISH interviews administered to cardiac patients by trained research nurses
and structured interviews administered by trained clinicians (weighted  
0.86) (14). Patients also completed the Beck Depression Inventory (BDI) (15),
a 21-item measure of the self-reported severity of depression.
Medically eligible patients who met the symptom criteria for either major
or minor depressive episode for at least 7 rather than the usual 14 days could
be enrolled in ENRICHD if they had a prior episode of MD. However, only
patients who met the full DSM-IV criteria for MD, including a 14-day
duration, were included in the analysis.
Patients who met all medical inclusion criteria, but who did not meet the
depression criteria of the ENRICHD trial, were recruited for a nondepressed
comparison group for an ancillary study from three of the ENRICHD sites
(Washington University, St. Louis, Missouri; Duke University, Durham,
North Carolina; Harvard University, Boston, Massachusetts/Yale University,
New Haven, Connecticut). Additional criteria for enrollment in the compar-
ison group included a score of 10 on the BDI and no previous episodes
of MD.
Patients enrolled in the clinical trial were assigned randomly to either the
study intervention or to usual care (UC). Intervention patients received
individual, and in some cases, group cognitive behavior therapy weekly for up
to 6 months. Patients with severe depression (HAM-D score of 24), and
those who did not show at least a 50% decrease in BDI scores after 5 weeks,
were referred to study psychiatrists for consideration of pharmacotherapy.
Most of these patients were started on 50 mg/day sertraline, and the dosage
was subsequently adjusted up to a maximum of 200 mg/day, if needed. Nearly
all of these patients received the antidepressant for 12 months (13). The
nondepressed comparison patients did not receive a study-related interven-
tion, but they were followed for the duration of the study.
Follow-up assessments were performed annually beginning 6 months after
enrollment. The primary outcome of the ENRICHD trial was the combined
end point of all-cause mortality or recurrent nonfatal acute MI. Standardized,
group-masked classification of the major end points, including probable car-
diovascular and noncardiovascular death, was performed by the ENRICHD
Medical Endpoints Committee. Death certificates were obtained to document all
deaths. The primary end point for the present study was all-cause mortality.
Suspected cardiovascular mortality was also evaluated as a secondary end point.
Statistical Analyses

2 tests and analyses of variance were used to compare demographic and
medical variables across the three groups (i.e., initial episode of depression,
recurrent depression, nondepressed controls). Kaplan-Meier estimates and
covariate-adjusted Cox proportional hazards regression models were used to
describe the relationship between depression subgroup and survival. Schoen-
feld (16) and Martingale residuals (17) were used to test the Cox model
assumptions of proportional hazards and linearity of continuous covariates,
respectively. Variable-by-time interaction terms were also calculated to test
the proportional hazards assumption. Kaplan-Meier survival curves for the
three groups were compared with the log rank statistic (18).
A previously published, weighted index of independent risk factors for
all-cause mortality in the ENRICHD trial was used to adjust for possible
confounders (19). All major risk factors and cardiac treatments were initially
considered in this model, including smoking, hypertension, gender, current
heart failure, and being discharged on  blockers. The final risk score,
representing the best set of independent predictors for all-cause mortality for
the participants in the ENRICHD clinical trial, included age, diabetes, left
ventricular ejection fraction (LVEF), creatinine level, prior MI, history of
pulmonary disease, prior transient ischemic attack or stroke, history of heart
failure, Killip class at time of the index MI, and treatment with vasodilators.
Baseline BDI scores, and selective serotonin reuptake inhibitor (SSRI) anti-
depressant use during the study, which was previously shown to be associated
with improved survival in the ENRICHD trial (20), were also included in the
adjusted models. Because SSRI use varied throughout the follow-up period, it
was modeled as a time-dependent covariate, as described by Taylor and
colleagues (20).
Multiple imputation (SAS Proc MI) was used to impute missing data,
which occurred in 3% to 10% of cases for the covariables included in the
statistical models (21). Survival outcomes were not included in the imputation
model. All analyses were performed on 50 complete data sets in which
missing values were replaced with values estimated from observed variables.
The resulting model estimates were then combined for statistical inference.
SAS 9.1.3 software (SAS Institute, Inc., Raleigh, North Carolina) was used to
perform all statistical analyses.
RESULTS
A total of 920 patients enrolled in the ENRICHD study
who met the full DSM-IV criteria for major depression at the
time of enrollment, including the 14-day episode duration
criterion, and 408 patients who were free of depression but
otherwise eligible for the ENRICHD study, were included in
the present analyses. Three hundred seventy (40%) of the
patients who met the criteria for MD at enrollment reported
this to be their first depressive episode, and 550 (60%) re-
ported having one or more previous episodes. Comparisons of
the medical and demographic characteristics of the three
groups are presented in Table 1. There are many demographic
and medical differences between both of the depressed groups
and the nondepressed patients, including a higher proportion
of women and a higher prevalence of diabetes. These differ-
ences have been reported in earlier studies (22,23).
During a median follow-up of 29 months, 3.4% of the
nondepressed patients died, compared with 18.4% of the pa-
tients with first-time MD, and 11.8% of those with recurrent
MD. There was no difference in survival between interven-
tion versus UC arms for either first depressive episode
(20% versus 17%, p  .23) or recurrent depression cases
(11% versus 12%, p  .61). Consistent with the results of
the ENRICHD trial (13), there were no differences in
survival overall between patients who received the inter-
vention and those in the UC arm (log rank: 
2  0.17; df 
1; p  .68). Thus, treatment arm assignment was not
included in the primary analyses.
Kaplan-Meier survival curves for the three groups are pre-
sented in Figure 1. The omnibus test of differences in survival
among the groups was significant (log rank test: 
2  38.4;
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three groups with a Tukey adjustment for multiple comparisons
showed that both recurrent (
2  10.4; df  1; p  .004) and
first-time (
2  38.2; df  1; p  .001) depressed groups
differed from the nondepressed group. First-time and re-
current depression groups also differed from each other
(
2  5.8; df  1; p  .04).
Unadjusted hazard ratios (HRs) were estimated from a Cox
proportional regression model for patients with first-time MD
and those with recurrent MD, each compared with the refer-
ence group of nondepressed patients. Both first-time MD
(HR  5.2; 95% Confidence Interval (CI)  2.9–9.3; p 
.001) and recurrent MD (HR  3.3; 95% CI  1.8–5.9; p 
.001) predicted shorter survival. Patients with a first time
depression were at higher risk than those with recurrent de-
pression (HR  1.6; 95% CI  1.2–2.2; p  .008). Adjusting
for the ENRICHD all-cause mortality risk score, initial BDI
score, and SSRI antidepressant use, the difference in adjusted
survival between those with recurrent MD and those with a
first episode of MD remained significant (HR  1.4; 95%
CI  1.0–2.0; p  .05). Similarly, after adjustment for co-
variates, survival time for those with first-time (HR  3.1;
TABLE 1. Demographic, Depression, and Medical Characteristics
a
Characteristic
First Episode Major
Depression
(n  370)
Recurrent Major
Depression
(n  550)
No Depression
(n  408)
p
1 versus 3 2 versus 3 1 versus 2
Demographics
Women 44.3% 54.2% 32.1% .001 .001 .003
Married 60.4% 55.0% 78% .001 .001 .10
Education (12 years) 68.4% 71.2% 77.0% .008 .05 .37
Age (years) 60.7  12.4 58.4  12.2 61.1  10.6 .86 .001 .01
PSS 60.2  15.2 57.6  16.2 NA
b .02
Depression
BDI (Base) 19.4  8.2 22.2  8.4 3.9  2.9 .001 .001 .001
BDI (6 months) 10.5  9.6 13.7  9.5 NA
b —— .001
Change in BDI (B - 6 months) 8.3  9.8 8.5  10.2 — — — .81
No. prior depression episodes 0 3.1  3.9 0 — — —
Baseline antidepressants 5% 15.5% 1.8% .01 .001 .001
Antidepressants at any time 19.5% 34.6% 5.7% .001 .001 .001
Family history of depression 16.8% 42.7% 14.9% .51 .001 .001
Risk factors/history
Total cholesterol (mg/dl) 198  47.9 202  61.1 184  47.3 .02 .0002 .75
BMI (kg/m
2) 28.4  5.8 29.5  6.4 28.4  4.8 .99 .02 .02
Systolic blood pressure
(mm Hg)
126.7  20.2 122.9  20.0 122.2  18.1 .005 .86 .01
Diabetes mellitus 37.4% 38.2% 22.3% .001 .001 .80
History hypercholesterolemia 61.3% 66.4% 49.1% .001 .001 .13
Heart disease in 1st degree
relatives
70.1% 70.2% 67.2% .40 .33 .97
History CHF 18.8% 17.9% 4.4% .001 .001 .73
History PVD 13.0% 17.7% 5.6% .004 .001 .06
Previous AMI 29.1% 29.2% 20.3% .005 .002 .98
History CABG 16.4% 13.4% 10.5% .02 .18 .20
History PTCA 17.5% 17.1% 10.3% .004 .003 .90
History stroke/TIA 9.1% 11.3% 5.8% .08 .003 .29
Cigarette smoker (current) 29.2% 37.5% 26.1% .35 .002 .01
History of hypertension 63.3% 65.0% 52.4% .002 .001 .61
Post-MI medical status
ENRICHD all-cause mortality
risk score
3.9  1.1 3.8  1.1 3.7  0.9 .002 .02 .57
Q wave 27% 29% 32% .09 .24 .51
Creatinine 1.3 mg/dl 18.0% 17.6% 15.4% .33 .37 .87
LVEF (40%) 27.6% 27.5% 23.0% .17 .15 .97
Killip class III–IV 10.3% 9.8% 4.4% .002 .002 .82
Post-MI CABG 21.2% 15.8% 13.0% .003 .25 .04
Post-MI PTCA 43.8% 46.6% 67.3% .001 .001 .40
Thrombolytic therapy 49.6% 32.5% 33.6% .001 .74 .001
PSS  Perceived Social Support; BDI  Beck Depression Inventory; BMI  body mass index; CHF  coronary heart failure; PVD  peripheral vascular
disease; AMI  acute myocardial infarction; CABG  coronary artery bypass graft; TIA  transient ischemic attack; MI  myocardial infarction; ENRICHD 
Enhancing Recovery In Coronary Heart Disease; LVEF  left ventricular ejection fraction; PTCA  percutaneous transluminal coronary angioplasty.
a Continuous variables are reported as (mean  standard deviation); categorical variables are percentage of subjects with the characteristic.
b Not administered to nondepressed patients.
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95% CI  1.1–4.4; p  .03) remained significantly less than
for nondepressed patients.
In a secondary analysis, unadjusted HRs for cardiovascu-
lar-specific mortality were again estimated using Cox regres-
sion. Death likely due to cardiovascular causes occurred in
2.5% of the nondepressed patients, 11.1% of the patients with
first-time MD, and 7.6% of those with recurrent MD. First-
time MD (HR  4.5; 95% CI  2.3–9.0; p  .001) and
recurrent MD (HR  3.0; 95% CI  1.5–6.1; p  .002)
predicted shorter survival from cardiovascular-related mortal-
ity, although the difference in survival between the two groups
only approached significance (HR  1.5; 95% CI  0.97–2.3;
p  .07). After adjusting for the ENRICHD all-cause mortal-
ity risk score, initial BDI score, and SSRI antidepressants, the
effects for first-time MD remained significant (HR  2.7;
95% CI  1.2–6.0; p  .02), whereas the effect for recurrent
MD was only marginal (HR  2.1; 95% CI  0.9–4.9; p 
.09). Cardiovascular-related mortality did not differ between
the recurrent MD (reference group) and first episode of MD
subgroups (HR  1.3; 95% CI  0.80–2.0; p  .31).
To determine whether 6-month depression remission rates
differed between the two depressed groups, 
2 analyses were
performed separately for patients in the intervention and UC
groups. Remission of depression was defined in the ENRICHD
trial as a BDI score of 7 at the 6-month assessment. The
6-month BDI was completed by 80% of the ENRICHD partici-
pants. In the intervention group, 57% of those with first-time de-
pression remitted by 6 months, compared with 41% of those who
enrolled with recurrent depression (
2  8.4, df  1; p  .004). In
the UC group, 40% of the patients with first-time depression and
20% of those who enrolled with recurrent depression remitted at
6 months (
2  16.0, df  1; p  .001). However, the difference
between the intervention and UC groups in 6-month BDI change
scores did not differ by initial (mean  3.3) versus recurrent
major depressive episode (mean  3.9; F  0.18; df  1; p 
.67), although the baseline levels did (first  19.4  8.2 versus
recurrent  22.2  8.4), suggesting that the difference in remis-
sion rates may be due to lower baseline depression scores in the
group with an initial depressive episode.
DISCUSSION
Participants in the ENRICHD clinical trial with a first
episode of MD had poorer survival (18.4% all-cause mortal-
ity) than those with recurrent MD (11.8%), and both groups
had significantly poorer survival than did the nondepressed
patients (3.4% all-cause mortality). These differences per-
sisted after adjusting for baseline BDI score, SSRI antidepres-
sant use, and other medical and demographic predictors of
mortality. The results of a secondary analysis of cardiovascu-
lar deaths found similar results, but the two depression groups
did not differ even though the hazard was similar to that for
all-cause mortality (1.3 versus 1.4). Only 83 of the 133 total
deaths were classified as being clearly cardiovascular-related,
suggesting that insufficient statistical power may explain the
lack of significance.
The findings of the primary analysis differ somewhat from
those of five other studies of first-time versus recurrent de-
pression and survival post MI. In a secondary analysis, Les-
pe ´rance and colleagues found an 18-month post-MI mortality
rate of 40% in 15 patients with recurrent MD, compared with
10% in 20 patients with first-time depression (6). In a more
recent study of a cohort of 750 post-acute coronary syndrome
(ACS) patients, Grace et al. found that depression (BDI score
of 10) at the time of the MI was a significant predictor of
all-cause mortality, but only in patients who had never before
been depressed (9). Thus, only new-onset depression without
prior depression predicted survival. It is not clear, however,
whether these patients were depressed before or only after
the MI.
In a study of 468 patients, de Jonge and colleagues adminis-
tered a depression interview at 3 and 12 months after an acute MI
(7). They found that, of the patients who became depressed in the
year post MI, only those who were depressed for the first time
after the MI were at increased risk of cardiovascular mortality
and cardiovascular readmissions. As in Grace et al. (9), those
who became depressed but who had a history of earlier episodes
of depression were not at greater risk for cardiac events.
Dickens and colleagues studied 588 patients with a recent
MI (8). Patients who were depressed at 12 months after the
MI, but not those who reported having been depressed in the
week before the MI (HADS score of 17), were at greater risk
for cardiovascular-related death during the follow-up period.
It is not clear from this report whether patients were depressed
at or some time during the previous 12 months.
In the most recent report, Parker and colleagues adminis-
tered a depression interview to 489 patients post ACS, and
interviewed them again by phone at 1 and 12 months (24).
Neither a history of depression before the MI nor depression
at the time of the MI was found to be associated with a
combined end point of cardiovascular mortality or cardiac
hospitalization. However, similar to Grace et al. and de Jonge
et al., depression that began after an ACS admission was a risk
Figure 1. Kaplan-Meier survival curves for initial major depression, recur-
rent major depression, and no depression.
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and de Jonge et al., the risk was present in patients with a
depression after the event regardless of whether there were
prior episodes of depression. That is, the timing of the onset of
depression in relationship to the MI, and not whether it was an
initial or recurrent depressive episode, determined its impact.
Unfortunately, the ENRICHD interviewers did not determine
the precise onset of the current depressive episode so this
could not be evaluated in the present study.
Although there are methodological differences among
these five studies of post-MI or ACS patients, including the
use of interview-based depression diagnostic criteria versus
self-report inventories, different end points (all-cause mortal-
ity, cardiovascular-related mortality, and cardiac events), and
different time points for assessment of depression, none of
these differences seem to explain the contradictory findings.
Determining depression history is difficult, at best, and often
unreliable (25). It seems likely that this difficulty is magnified
when interviewing someone who just experienced a life-
threatening medical event. Thus, it is possible that differences
in depression history ascertainment may at least partially explain
some of the variation in the findings.
Nevertheless, the preponderance of evidence now seems to
suggest that an initial episode of depression after an acute MI
carries a higher risk of death than does a recurrent episode,
especially if its onset occurs after the acute cardiac event. Why
patients with an initial depressive episode would tend to be at
higher risk than those depressed patients with prior depressive
episodes is not clear.
Two earlier studies found that patients who were having
their first major depressive episode at the time of diagnostic
coronary angiography had more severe coronary artery dis-
ease than did those patients with a recurrent episode of de-
pression (26,27). Furthermore, first episodes of depression
relatively late in life could be manifestations of cerebrovas-
cular disease in some cases (28,29). Late-life depression has
been associated with white matter hyperintensities on mag-
netic resonance imaging (MRI) scans, suggesting cerebrovas-
cular abnormalities, and with mild-to-moderate cognitive
impairment (30). Thus, one explanation for the present
findings is that patients with an initial episode of depres-
sion may have more significant coronary artery disease or
cerebrovascular disease than those with recurrent MD,
placing them at higher risk for mortality.
Coronary angiography, MRI scans, and tests of cognitive
functioning were not routinely performed on ENRICHD par-
ticipants before or after the index MI. However, risk factors
for coronary artery disease and cerebrovascular disease were
determined from systematic chart reviews. ENRICHD patients
with initial depressive episodes were younger than those with
recurrent depression by an average of 2 years. Mean systolic
blood pressure was slightly higher (4 mm Hg), but well within
normal limits (mean  126.7  20.2 mm Hg). Patients with
initial episodes were more likely to have coronary bypass
surgery after their MI, but were no more likely to have
coronary angioplasty. On the other hand, they were less likely
to smoke and slightly less likely to have had a history of
peripheral vascular disease than were those with recurrent
depression. There were no differences between the groups in
history of stroke, prior MI, revascularization, hypercholester-
olemia, total serum cholesterol levels, or family history of
stroke or heart disease. Thus, there was little evidence that
these patients were at higher risk for cerebrovascular disease,
or that they had more significant coronary artery disease
before the index MI. Nevertheless, neither of these possibili-
ties can be entirely ruled out.
It has also been suggested that acute MI patients with initial
depressive episodes may have more severe coronary heart
disease, compared with those with recurrent depression (7,31).
However, little evidence was found for this in the present
study. There were no differences between these groups in
Killip class, LVEF, heart failure, prior MI, the ENRICHD
all-cause mortality risk score, or the presence of other medical
comorbidities. One interesting and unexpected finding was
that a higher proportion of patients with initial major depres-
sive episodes had received thrombolytic therapy, compared
with patients with recurrent MD. There were no differences
between these subgroups in the proportion of patients with
documented Q-wave MIs. In any case, receiving thrombolytic
therapy was not associated with survival in this study.
Patients with recurrent depression had slightly more severe
depression, were more likely to have a family history of
depression, to be female, to have less perceived social support,
and to be on antidepressants at the baseline assessment. Al-
though the data were only available for about 80% of cases,
patients with initial or recurrent major depression experienced
similar changes in depression severity over the first 6 months
after the acute MI. However, because their depressions were
slightly more severe at baseline, those with recurrent depres-
sion also remained slightly more depressed than those with
first-time depression.
Initial major depressive episodes were more likely to
remit than were recurrent episodes, both in the intervention
and in the UC groups. However, this may have been due to
lower baseline depression scores in the patients who were
depressed for the first time. In any case, this finding is not
consistent with the results of two recent antidepressant
clinical trials.
Unlike our study, Lespe ´rance et al. (11) found no differ-
ence in HAM-D scores at baseline between initial and recur-
rent depressive episodes (29.6  6.8 versus 29.8  6.7), but
patients with recurrent depression showed a larger response to
citalopram than did patients in their first major depressive
episode. Glassman et al. (10) reported a better response to
sertraline in patients with recurrent MD compared with pa-
tients experiencing an initial major depressive episode. Al-
though about 20% of patients in the ENRICHD intervention
arm received sertraline, most patients were treated solely with
cognitive behavior therapy. It is possible that patients with
initial major depressive episodes after an acute MI respond
better to psychotherapy, and those with recurrent depression
respond better to antidepressant therapy. However, the study
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had little effect on either type of depressive episode.
One possible explanation for the finding that a first episode
of depression is a greater risk for mortality than a recurrent
depression is that those patients with prior episodes of depres-
sion at greatest risk died as a result of the index MI. Those
who survived the index MI may have been at lower risk for
reasons that are not presently known. These patients may
remain at lower risk in the months after the index MI.
One of the limitations of this study is that the sample was
composed of participants enrolled in a clinical trial or in an
ancillary study of that trial. As a result, the findings may not
generalize to all post-MI patients, as patients who were too
sick or debilitated to participate in the trial were excluded.
Furthermore, we know little about the duration of the depres-
sion episodes that were identified at baseline, the rates of
relapse and recurrence, peak severity, or the cumulative ex-
posure to depression over the total follow-up period for either
group of depressed patients. This is a shortcoming of this and
of most previous studies. A better understanding of the course
of depression after acute MI and its relationship to mortality
risk remains one of the most important goals in this area of
study (32). Finally, it is possible that high-risk patients with
prior episodes of depression were less likely to volunteer for
the study than those with a first episode of depression, al-
though we have no evidence for this. More than half of the
patients in our sample had recurrent depression, similar to
that reported in a previous study of depression in post-MI
patients (31).
In summary, in a large sample of well-characterized
post-MI patients with interview-based depression diagnoses,
those with initial episodes of MD tended to have poorer
survival than those with recurrent major depression, but both
had poorer survival than did patients without depression.
Exploratory analyses suggest that the greater risk of mortality
seen among patients with an initial episode of MD cannot be
explained by more severe cardiac illness at index or by being
at higher risk for more severe coronary artery or cerebrovas-
cular disease. Future research should attempt to confirm this
finding and seek to identify the factors contributing to a
greater risk of mortality after acute MI in this common sub-
type of MD.
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